Vilin Bio Med holds NCLT-ordered meeting for Chemgenix amalgamation scheme

Regulatory & Legal View source PDF Explain this filing

VILINBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹52.05

prior close

₹54.65

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%+6.6% vs market

On the reaction day the stock moved 6.6 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+5.0-1.6+6.6

Next day

+2.3-1.0+3.3

—-2.6—

-2.8-5.1+2.4

-0.1-6.1+6.0

-2.1-8.3+6.2

-2.3pendingpending

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vilin Bio Med held NCLT-ordered meetings of equity shareholders and unsecured creditors on October 15, 2026 to seek approval for the Scheme of Amalgamation with Chemgenix Laboratories Private Limited under Sections 230 to 232 of the Companies Act, 2013. 12 shareholders attended (5 in person, 7 via video conference) and 1 creditor was present. Voting results are pending and will be announced after the Scrutinizer Report is received.

Likely market impact

Amalgamation with Chemgenix Labs moves to next stage; pending voting outcome. Watch for scrutinizer results to gauge shareholder and creditor support.